CLAIMS

1. An isolated antibody which specifically binds to Cadherin-17 comprising:
(a) a heavy chain comprising SEQ ID NO: 27; and
(b) the light chain comprising SEQ ID NO: 31.

2. An isolated antibody as claimed in claim 1, wherein the antibody is selected from the group consisting of full length antibodies, antibody fragments, single chain antibodies, bispecific antibodies, minibodies, domain antibodies, synthetic antibodies and antibody fusions, and fragments thereof.

3. An isolated antibody as claimed in claim 1 or claim 2, wherein the antibody further comprises an Fc domain, preferably wherein the Fc domain is human or a variant human Fc domain.

4. An isolated antibody as claimed in any one of claims 1-3, wherein the antibody is monoclonal.

5. An isolated antibody as claimed in any one of claims 1-4, wherein the antibody contains or is conjugated to a therapeutic moiety, preferably a cytotoxin, a drug or a radiotoxin.

6. An isolated antibody as claimed in claim 5, wherein the therapeutic moiety is a duocarmycin.

7. An isolated antibody as claimed in any one of claims 1-6, wherein the antibody elicits antibody-dependent cellular cytotoxicity (ADCC).

8. A pharmaceutical composition comprising an antibody as claimed in any one of claims 1-4, or 7, or an antibody conjugate as claimed in claim 5 or claim 6, optionally together with a pharmaceutically acceptable carrier.

9. An antibody as claimed in any one of claims 1-7 or a pharmaceutical composition as claimed in claim 8, for use as a medicament or for use in therapy or diagnosis.

10. Use of an isolated antibody as claimed in any one of claims 1 to 7 in the manufacture of a medicament for treating or preventing a disease associated with Cadherin 17.

11. The use as claimed in claim 10, wherein the disease is cancer.

12. The use as claimed in claim 11, wherein the cancer is colon cancer.

13. The use as claimed in claim 11, wherein the cancer is gastric cancer or pancreatic cancer.

14. Use of an isolated antibody which specifically binds to Cadherin-17 (CDH17), comprising:
a) a heavy chain variable region comprising:
i) a first CDR comprising a sequence at least 80% identical to SEQ ID NO: 36;
ii) a second CDR comprising a sequence at least 82% identical to SEQ ID NO: 2;
iii) a third CDR comprising a sequence at least 90% identical to SEQ ID NO: 39; and
b) a light chain variable region comprising:
i) a first CDR comprising a sequence at least 80% identical to SEQ ID NO: 4;
ii) a second CDR comprising a sequence at least 90% identical to SEQ ID NO: 40; and
iii) a third CDR comprising a sequence at least 90% identical to SEQ ID NO: 41 in the manufacture of a medicament for treating gastric cancer or pancreatic cancer.

15. The use as claimed in claim 14, wherein the antibody contains or is conjugated to a duocarmycin.

CLAIMS

1. An isolated antibody which specifically binds to Cadherin-17, comprising:
a) a heavy chain variable region comprising:
i) a first CDR comprising an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 46;
ii) a second CDR comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 47;
iii) a third CDR comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 48; and
b) a light chain variable region comprising:
i) a first CDR comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 49;
ii) a second CDR comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 50; and
iii) a third CDR comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 51.

2. An isolated antibody as claimed in claim 1, wherein:
(a) the heavy chain framework region comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 26; and/or
(b) the light chain framework region comprises an amino acid sequence with at least 85% sequence identity to SEQ ID NO: 31.

3. An isolated antibody as claimed in any one of claims 1-2, wherein the antibody is selected from the group consisting of full length antibodies, antibody fragments, single chain antibodies, bispecific antibodies, minibodies, domain antibodies, synthetic antibodies and antibody fusions, and fragments thereof.

4. An isolated antibody as claimed in any one of claims 1-3, wherein the antibody further comprises an Fc domain, preferably wherein the Fc domain is human or a variant human Fc domain.

5. An isolated antibody as claimed in any one of claims 1-4, wherein the antibody is monoclonal.

6. An isolated antibody as claimed in any one of claims 1-5, wherein the antibody contains or is conjugated to a therapeutic moiety, preferably a cytotoxin, a drug or a radiotoxin.

7. An isolated antibody as claimed in any one of claims 1-6, wherein the antibody elicits antibody-dependent cellular cytotoxicity (ADCC).

8. A pharmaceutical composition comprising an antibody as claimed in any one of claims 1-7, optionally together with a pharmaceutically acceptable carrier.

9. An antibody as claimed in any one of claims 1-7 or a pharmaceutical composition as claimed in claim 8, for use as a medicament or for use in therapy or diagnosis.

10. Use of an isolated antibody as claimed in any one of claims 1 to 7 in the manufacture of a medicament for treating or preventing a disease associated with Cadherin 17.

11. The use as claimed in claim 10, wherein the disease is cancer.

12. The use as claimed in claim 11, wherein the cancer is selected from the group consisting of gastric cancer, pancreatic cancer and colon cancer.

13. Use of an isolated antibody which specifically binds to Cadherin-17 (CDH17), comprising:
a) a heavy chain variable region comprising:
i) a first CDR comprising a sequence at least 80% identical to SEQ ID NO: 36;
ii) a second CDR comprising a sequence at least 82% identical to SEQ ID NO: 2;
iii) a third CDR comprising a sequence at least 90% identical to SEQ ID NO: 39; and
b) a light chain variable region comprising:
i) a first CDR comprising a sequence at least 80% identical to SEQ ID NO: 4;
ii) a second CDR comprising a sequence at least 90% identical to SEQ ID NO: 40; and
iii) a third CDR comprising a sequence at least 90% identical to SEQ ID NO: 41 in the manufacture of a medicament for treating gastric cancer, pancreatic cancer or colon cancer.